Navigation Links
Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
Date:5/4/2008

disease. Phase 1, 2 and 3 study data have been reported showing that motavizumab appears to have a similar safety and pharmacokinetic profile to Synagis(R) (palivizumab) in infants. Additionally, in early phase studies children treated with motavizumab had reduced RSV replication in the upper respiratory tract. In its pivotal clinical trial, which was a head-to-head comparative trial with Synagis, motavizumab demonstrated non-inferiority with a 26-percent relative reduction in RSV hospitalizations due to RSV, which was its primary endpoint, and a 50- percent relative reduction in the incidence of RSV lower respiratory tract infections requiring outpatient management, one of its secondary endpoints. Rates of adverse events, serious adverse events and study drug discontinuations were balanced between treatment groups.

About Synagis

Synagis (palivizumab) is indicated for the prevention of serious lung infections caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Synagis is given as a shot, usually in the thigh muscle, each month during the RSV season. The first dose of Synagis should be given before RSV season begins. Children who develop an RSV infection while receiving Synagis should continue the monthly dosing schedule throughout the season. Synagis has been used in more than one million children in the U.S. since its introduction in 1998.

Synagis is not currently recommended as a preventive measure among Native American infants at high risk for serious RSV disease.

Very rare cases (<1 per 100,000 patients) of severe allergic reactions such as anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. These rare reactions may occur when any dose of Synagis is given, not just the first one. Also, rare but serious side effects can occur, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin.

Other side effects with Synag
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... CLARA, Calif., Feb. 18 Align Technology, Inc. (Nasdaq: ... notified of a purported declaratory judgment action filed against the ... United States District Court for the Southern District of Texas. ... 2009, but has not been served with a copy of ...
... supported entry into Company,s current Phase, ... 18 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: ... announced that The Journal of Urology has published ... results for the Company,s proprietary Mycobacterial Cell Wall ...
... a world-leading provider of Hosted Microsoft Exchange, presents competitive risk-proof, out-of-the-box ... ... February 18, 2009 -- SherWeb , a global leader in ... Reseller Program last week. The newly implemented program provides IT ...
... Change" Campaign Part of International Effort to Combat Rare Diseases That Collectively ... ... CA (PRWEB) February 18, 2009 -- Students at Albany High School in ... some change to help support the first annual World Rare Disease Day, ...
... Red Wine & More , ... Mount Kisco, NY (PRWEB) February 18, ... resveratrol . It,s been shown to increase the life spans of yeast, ... School and the National Institute on Aging created a stir when they ...
... Regardless of where they are born in ... for many life-threatening disorders, a remarkable public health advance of ... today by the March of Dimes.All 50 states and the ... for 21 or more of the 29 serious genetic ...
Cached Medicine News:Health News:Align Technology Asserts ClearCorrect Complaint Is Without Merit 2Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 2Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 3Health News:Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology 4Health News:SherWeb Launches Unique White Label Exchange Reseller Program 2Health News:Albany High School Students Unite To Raise Awareness and Funds For World Rare Disease Day 2009 2Health News:Albany High School Students Unite To Raise Awareness and Funds For World Rare Disease Day 2009 3Health News:Physician Develops Resveratrol Evidence-Based Nutraceutical for Heart Health 2Health News:Physician Develops Resveratrol Evidence-Based Nutraceutical for Heart Health 3Health News:States Expand Newborn Screening for Life-Threatening Disorders; New March of Dimes Report Finds State-By-State Gaps Nearly Eliminated 2Health News:States Expand Newborn Screening for Life-Threatening Disorders; New March of Dimes Report Finds State-By-State Gaps Nearly Eliminated 3Health News:States Expand Newborn Screening for Life-Threatening Disorders; New March of Dimes Report Finds State-By-State Gaps Nearly Eliminated 4
... FT is an affordable full-field, autoperimeter that includes ... least 40%. It has a small footprint and ... and easy two-button operation making it not only ... FT is the workhorse of the Paradigm family ...
... incisional corneal surgery has long ... of the ophthalmology practice. To ... the technical skills and a ... quality. The new "Newman Astigmatic ...
... Gentamycin sulfate is effective against gram positive ... mycoplasma, by interfering with bacterial protein synthesis ... ribosomes. Its suggested working concentration of 50 ... mammalian cells, thereby making a gentler alternative ...
... approach to practice management, built to address the ... market. OPIE was created by practicing O&P professionals ... this field, so it thinks the way you ... anything else available. If you believe there is ...
Medicine Products: